64 completed, 4 terminated, 4 withdrawn, 2 recruiting. 29 Phase 1, 20 Phase 2, 9 Not applicable, 9 Phase 3, 8 Phase 4.
Follow Plasmodium Falciparum Malaria: new trials by email Literature Review of Plasmodium Falciparum Malaria trials Research Report on Plasmodium Falciparum Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| R21/MM Dosing, Presentations, and Preservatives 10μg R21/50μg Matrix-M, 5μg R21/50μg Matrix-M with adaptor preservative free, 5μg R21/50μg Matrix-M with 2PE preservative - Plasmodium Falciparum Malaria, Malaria | Phase 4 | Not yet recruiting | University of Oxford | 375 | 2026-08-15 | 2026-08-04 |
| Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT) R21/Matris-M Malaria vaccine - Malaria, PLASMODIUM FALCIPARUM MALARIA | Recruiting | Clinton Health Access Initiative Inc. | 20000 | 2026-07-14 | 2026-08-06 | |
| Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant Pfs25-IMX313, Pfs48/45 - Plasmodium Falciparum Malaria | Phase 1 / Phase 2 | Active not recruiting | University of Oxford | 56 | 2025-07-07 | 2026-02-23 |
| Mass Vaccine and Drug Administration, Bangladesh DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™ - Plasmodium Falciparum Malaria | Phase 4 | Recruiting | University of Oxford | 10000 | 2025-02-15 | 2025-12-18 |
| Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites. GA2, GA1, Placebo - Plasmodium Falciparum Malaria | Phase 1 / Phase 2 | Completed | Leiden University Medical Center | 43 | 2021-09-27 | 2023-01-13 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria artemether:lumefantrine (2.5 mg:30 mg) - Plasmodium Falciparum Malaria | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 28 | 2020-12-21 | 2026-01-13 |
| Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand Case Management and Follow-up, Reactive focal mass drug administration (rfMDA) - Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria | Not applicable | Completed | University of California, San Francisco | 14977 | 2020-11-01 | 2026-04-29 |
| Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic Household Reactive Case Detection, RACD of cases' co-workers/co-travelers, Case Management and Follow-up - Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria | Not applicable | Withdrawn | University of California, San Francisco | 2020-09-20 | 2026-04-29 | |
| Additional Screening With Sensitives RDTs and Malaria Additional screening using ultra sensitive RDTs, Dihydroartemisinin-piperaquin, Reminders - Plasmodium Falciparum Malaria, Malaria Diagnosis | Phase 3 | Completed | Institut de Recherche en Sciences de la Sante, Burkina Faso | 340 | 2020-08-31 | 2023-03-30 |
| Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine Antimalarials, pyronaridine-artesunate, Antimalarials, Artemether + Lumefantrine - Malaria Fever, Plasmodium Falciparum Malaria | Phase 2 / Phase 3 | Completed | University of Ibadan | 172 | 2019-05-20 | 2022-04-07 |
| Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia Pneumonia, Bacterial, Viral Infection | Completed | Boston University | 837 | 2019-02-11 | 2022-05-31 | |
| Mass Screening and Treatment for Reduction of Falciparum Malaria Ultrasensitive Rapid Diagnostic Test (URDT), Antimalarials - Plasmodium Falciparum Malaria | Not applicable | Completed | University of Oxford | 5542 | 2018-11-01 | 2024-03-27 |
| Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea HS-RDT - Plasmodium Falciparum Malaria, Pregnancy Malaria | Completed | Foundation for Innovative New Diagnostics, Switzerland | 930 | 2018-08-15 | 2026-09-17 | |
| Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic Standard RDT and HS-RDT, Artemether-lumefantrine, Primaquine Phosphate - Plasmodium Falciparum Malaria | Phase 4 | Completed | University of California, San Francisco | 39968 | 2017-11-28 | 2021-02-23 |
| Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar Artesunate-amodiaquine given with single low dose primaquine - Plasmodium Falciparum Malaria | Phase 4 | Completed | Professor Anders Björkman | 146 | 2017-05-09 | 2018-12-12 |
| SJ733 Induced Blood Stage Malaria Challenge Study (+)-SJ000557733 - Plasmodium Falciparum Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 17 | 2016-09-13 | 2020-05-05 |
| DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax DSM265 400mg, DSM265 xmg, DSM265 ymg - Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria | Phase 2 | Completed | Medicines for Malaria Venture | 45 | 2016-01-01 | 2016-06-22 |
| Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria Imatinib combination therapy, Dihydroartemisinin-piperaquine - Plasmodium Falciparum Malaria | Phase 1 | Completed | HuLow | 15 | 2015-11-01 | 2021-02-11 |
| Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos KAE609, Piperaquine Phosphate - Plasmodium Falciparum Malaria | Phase 1 | Terminated | Novartis Pharmaceuticals | 8 | 2015-07-01 | 2019-07-23 |
| A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01), ChAd63 ME-TRAP (5 x 10^10 vp) - Plasmodium Falciparum Malaria | Phase 1 / Phase 2 | Completed | University of Oxford | 48 | 2015-01-01 | 2015-12-03 |
Showing 20 of 76. Sign in to see all of them.
Malaria, Falciparum (76) · Malaria (49) · Malaria, Vivax (4) · Disease (2) · Acidosis, Lactic (1) · Burkitt Lymphoma (1) · Death (1) · Dyspnea (1) · Hypoxia (1) · Malaria, Cerebral (1) · Parasitic Diseases (1) · Pneumonia, Bacterial (1) · Protozoan Infections (1) · Recurrence (1) · Respiratory Tract Infections (1)
Infections (76) · Mosquito-Borne Diseases (76) · Vector Borne Diseases (76) · Parasitic Diseases (75) · Protozoan Infections (75) · Malaria (27) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Hemic and Lymphatic Diseases (2) · Respiratory Tract Diseases (2) · Acid-Base Imbalance (1) · Acidosis (1) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1)
Artemether, Lumefantrine Drug Combination (7) · Primaquine (3) · Rabies Vaccines (3) · fanasil, pyrimethamine drug combination (3) · Antimalarials (2) · Artesunate (2) · Azithromycin (2) · Case Management (2) · Chloroquine (2) · Immunization (2) · Proguanil (2) · Quinine (2) · pyronaridine tetraphosphate, artesunate drug combination (2) · AS01B adjuvant (1) · Aluminum Hydroxide (1)
National Institute of Allergy and Infectious Diseases (NIAID) (18) · University of Oxford (10) · U.S. Army Medical Research and Development Command (6) · Medicines for Malaria Venture (4) · Professor Anders Björkman (3) · Sanaria Inc. (3) · University of California, San Francisco (3) · Institute of Tropical Medicine, Belgium (2) · Novartis Pharmaceuticals (2) · Radboud University Medical Center (2) · Anders Björkman (1) · Armed Forces Research Institute of Medical Sciences, Thailand (1) · Boston University (1) · Case Western Reserve University (1) · Clinton Health Access Initiative Inc. (1)
United States (9) · Burkina Faso (7) · Tanzania (7) · Thailand (7) · Kenya (6) · Mali (5) · Netherlands (5) · United Kingdom (5) · The Gambia (4) · Cambodia (3) · Ghana (3) · Laos (3) · Uganda (3) · Australia (2) · Bangladesh (2)
Adam Bennett, MA, PhD (3) · Adrian V S Hill, MD (3) · Andreas Martensson (2) · Graham S Cooke (2) · Mwinyi I Msellem (2) · Saul N Faust (2) · Sornchai Looareesuwan, MD (2) · Abduallah S Ali (1) · Abdullah Ali (1) · Adrian VS Hill (1) · Alejandro Llanos, Professor (1) · Andreas Martensson, PhD (1)
PMID 24970846, PMID 41014333, PMID 12011004, PMID 12742586, PMID 16163624, PMID 16960779, PMID 17093247, PMID 17442466, PMID 17467344, PMID 17550470, PMID 17940609, PMID 18253503, PMID 18671254, PMID 18698359, PMID 19038036, PMID 19093004, PMID 19366448, PMID 20140214, PMID 20687837, PMID 21916638, PMID 22768052, PMID 23358640, PMID 23433102, PMID 23599283, PMID 24035558, PMID 24079306, PMID 24260195, PMID 24872326, PMID 24891429, PMID 25336730, PMID 26303805, PMID 26774243, PMID 26908756, PMID 27010542, PMID 27013512, PMID 27087149, PMID 27307573, PMID 27644034, PMID 27697302, PMID 28081133, PMID 28143518, PMID 28199305, PMID 28282396, PMID 28806957, PMID 29165227, PMID 29438525, PMID 29522113, PMID 29909069, PMID 29917147, PMID 29929514
U01AI065683 (2), 2014 (1), N01AI085346 (1), R21AI140258 (1), U19AI065683 (1)